Patents by Inventor George R. Pettit

George R. Pettit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170100491
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 13, 2017
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Patent number: 9539342
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: January 10, 2017
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, acting for and on behlaf of Arizona State University
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Publication number: 20150344522
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Application
    Filed: May 6, 2015
    Publication date: December 3, 2015
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Patent number: 9175041
    Abstract: The present invention relates to the crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline. The present invention also relates to processes for preparing dolamethylleuine and dolaphenvaline. The present invention further relates to computer readable medium with crystal structural data and/or information stored thereon.
    Type: Grant
    Filed: April 25, 2012
    Date of Patent: November 3, 2015
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Thomas Smith, Jun-Ping Xu, Delbert Herald
  • Patent number: 9044518
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 2, 2015
    Assignee: ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Publication number: 20140179897
    Abstract: The present invention relates to the crystal structures of dolastatin 16, dolamethylleuine and dolaphenvaline. The present invention also relates to processes for preparing dolamethylleuine and dolaphenvaline. The present invention further relates to computer readable medium with crystal structural data and/or information stored thereon.
    Type: Application
    Filed: April 25, 2012
    Publication date: June 26, 2014
    Inventors: George R. Pettit, Thomas Smith, Jun-Ping Xu, Delbert Herald
  • Publication number: 20140023666
    Abstract: The present invention relates to new auristatin compounds and prodrugs thereof, compositions comprising them and uses thereof.
    Type: Application
    Filed: March 29, 2012
    Publication date: January 23, 2014
    Inventors: George R. Pettit, Fiona Hogan, Steven Toms
  • Patent number: 8633154
    Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: January 21, 2014
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona Acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Rui Tan, Robin K. Pettit
  • Publication number: 20130184201
    Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.
    Type: Application
    Filed: March 6, 2013
    Publication date: July 18, 2013
    Applicants: Arizona State University
    Inventors: George R. Pettit, Rui Tan, Robin K. Pettit
  • Patent number: 8415294
    Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: April 9, 2013
    Assignee: Arizona Board of Regents
    Inventors: George R. Pettit, Rui Tan, Robin K. Pettit
  • Patent number: 8053416
    Abstract: Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures elucidated. The new compounds exhibit significant cancer cell growth inhibition activity against a variety of murine and human cancer cell lines, and as such appear will be useful in the treatment of various forms of neoplastic disease.
    Type: Grant
    Filed: May 11, 2006
    Date of Patent: November 8, 2011
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of Arizona State University
    Inventors: George R. Pettit, Yuping Tang
  • Patent number: 7994320
    Abstract: The present invention provides prodrugs derived from the sparingly soluble anticancer isocarbostyril narciclasine, a component of various Narcissus species, said prodrugs having potential for use against animal and human cancers. Also disclosed is an efficient procedure for the synthetic conversion of narciclasine to several more soluble cyclic phosphate compounds, including “narcistatin”.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: August 9, 2011
    Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on behalf of Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Publication number: 20100197570
    Abstract: The present invention is directed to cyclodepsipeptide compounds having antineoplastic and/or antimicrobial activity, preferably Kitastatin 1. The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth in a host inflicted therewith by administering cyclodepsipeptide compounds to the inflicted host.
    Type: Application
    Filed: June 5, 2008
    Publication date: August 5, 2010
    Applicant: Arizona Board of Regents ,a body Corporate of the State of Arizona, Acting for and on Behalf of Ariz
    Inventors: George R. Pettit, Rui Tan, Robin K. Pettit
  • Publication number: 20100179108
    Abstract: The present invention involves use of the compounds narciclasine (2a) and 7-deoxy-narciclasine (2c), which are obtained via isolation from the medicinal plant species Narcissus (Amaryllidaceae), as precursors in a novel synthesis method in which each of these compounds are selectively hydrogenated to produce trans-dihydronarciclasine (1a) and 7-deoxy-trans-dihydronarciclasine (1c). Also described herein is a novel synthesis method for producing sodium narcistatin (11) from narciclasine (2a). Further described herein are certain novel 3,4-cyclic phosphate prodrugs, including sodium-7-deoxynarcistatin (8), sodium-7-deoxy-transdihydronarcistatin (9), and sodium transdihydronarcistatin (10).
    Type: Application
    Filed: March 15, 2010
    Publication date: July 15, 2010
    Applicant: AZ Board of Regents, a body corporate of the State of AZ, Acting for & on Behalf of AZ State Univ.
    Inventors: George R. Pettit, Noeleen Melody
  • Patent number: 7709643
    Abstract: The present invention involves use of the compounds narciclasine (2a) and 7-deoxy-narciclasine (2c), which are obtained via isolation from the medicinal plant species Narcissus (Amaryllidaceae), as precursors in a novel synthesis method in which each of these compounds are selectively hydrogenated to produce trans-dihydronarciclasine (1a) and 7-deoxy-trans-dihydronarciclasine (1c). Also described herein is a novel synthesis method for producing sodium narcistatin (11) from narciclasine (2a). Further described herein are certain novel 3,4-cyclic phosphate prodrugs, including sodium-7-deoxynarcistatin (8), sodium-7-deoxy-transdihydronarcistatin (9), and sodium transdihydronarcistatin (10).
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: May 4, 2010
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University
    Inventors: George R. Pettit, Noeleen Melody
  • Patent number: 7705188
    Abstract: Described herein are novel compounds having antineoplastic and antimicrobial activity, obtained via structural modifications of resveratrol and combretastatin A-4, methods for synthesis of these compounds, and their use in pharmaceutical composition and for use in the treatment of mammals having cancer. Examples of the novel compounds are: (Z)- and (E)-3,4?,5-trimethoxystilbene (4a, 4b); (Z)- and (E)-3,5-dimethoxy-4?-hydroxystilbene (14c, 14d); (Z)- and (E)-3-hydroxy-4?,5-dimethoxystilbene (14g, 14h); (Z)- and (E)-3,5-dihydroxy-4?-methoxy-stilbene (14k, 14l); sodium resverastatin dibenzyl phosphate ((Z)-3,5-dimethoxy-4-[O-bis(benzyl)phosphoryl]-stilbene) (14m); and sodium resverastatin phosphate (14n).
    Type: Grant
    Filed: April 10, 2003
    Date of Patent: April 27, 2010
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University
    Inventors: George R. Pettit, Matthew P. Grealish
  • Publication number: 20090298784
    Abstract: Described herein are novel cerebroside compounds, designated as Turbostatin 1, Turbostatin 2, Turbostatin 3, and Turbostatin 4. These compounds were extracted and isolated from the marine mollusk Turbo stenogyrus, and their structures elucidated. The new compounds exhibit significant cancer cell growth inhibition activity against a variety of murine and human cancer cell lines, and as such appear will be useful in the treatment of various forms of neoplastic disease.
    Type: Application
    Filed: May 11, 2006
    Publication date: December 3, 2009
    Inventors: George R. Pettit, Yuping Tang
  • Publication number: 20090221666
    Abstract: The present invention provides stilbene derived compounds having antineoplastic and/or antimicrobial activity. Preferred compounds of the invention include compounds of the formula (I) wherein R is Dap, Dap-Dil, Dap-Dil-Val, or Dap-Dil-Val-Dov; R1 is H, OH, or PO3Na2; and R2 and R3 are jointly —CH2— or each independently H, OH, CH3, or PO3Na2; and compounds of the formulas (II), (III) and salts thereof, wherein R and R1 are independently H or P(O)(OH). The present invention is further directed to methods of inhibiting cancer cell growth and/or microbial growth and compositions for use therewith.
    Type: Application
    Filed: May 12, 2006
    Publication date: September 3, 2009
    Inventors: George R. Pettit, Collin R. Anderson
  • Patent number: 7557096
    Abstract: Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agent. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble derivatives are herein denominated as “Combretastatin A-4 Prodrugs”.
    Type: Grant
    Filed: October 8, 2007
    Date of Patent: July 7, 2009
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, acting for an on behalf of the Arizona State University
    Inventors: George R. Pettit, Monte R. Rhodes
  • Patent number: 7547686
    Abstract: A new and more efficient synthesis of combretastatin A-3 (2a) was completed (8.4% overall yield) starting from methyl gallate and isovanillin with aldehyde 5 and phosphonium salt 8 as key intermediates. Conversion of combretastatin A-3 (2a) to a series of diphosphate prodrugs (lOa-lOl) containing selected anions was achieved. Both the diphosphate sodium (lOa) and potassium salts (lOc) displayed aqueous solubility in excess of 220 mg/ml at room temperature and good cancer cell line inhibitory activity.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: June 16, 2009
    Assignee: Arizona Board of Regents, a body corporate of the State of Arizona, Acting for and on Behalf of the Arizona State University
    Inventors: George R. Pettit, Mathew D. Minardi